BOULDER — OSI Pharmaceuticals Inc. is closing its 145-employee Boulder office as part of plans to consolidate its U.S. operations on a single campus in New York.
Officials for the Melville, N.Y.- based drugmaker said the consolidation — which will affect 350 people who work in Melville; Farmingdale, N.Y.; Boulder; and Cedar Knolls, N.J. — is intended to “simplify” its business operations.
“The past 10 years has been a remarkable journey as the company has successfully brought its first oncology product, Tarceva, to market and taken the business profitable,” Colin Goddard, OSI’s chief executive, said in a news release. “Nonetheless, we have recognized that we will only truly capture the full strategic value of our oncology franchise if we simplify our business by bringing together all the elements of our U.S. operations onto a single site.”
OSI has yet to file a notice with Colorado’s labor department under the Worker Adjustment and Retraining Notification Act, said Bill Thoennes, a spokesman for the Colorado Department of Labor and Employment.
Company officials were not immediately available for comment.
OSI has purchased a 43-acre site that includes 400,000 square feet of office space in Greenburgh, N.Y., and expects to begin the consolidation later this year, officials said. The company received incentives from the state of New York in connection with the move, OSI officials added.
OSI has had a presence in Boulder since 2001, when it purchased Gilead’s Boulder offices and a pipeline of cancer-fighting clinical candidates for $200 million.
Gilead had acquired the operations two years earlier in its merger with Boulder-bred NeXstar Pharmaceuticals Inc.
